Objective To catalogue the risk of PML with the currently available disease modifying
therapies (DMTs) for multiple sclerosis (MS). Background All DMTs perturb the immune …

This evidence‐and consensus‐based guideline on the treatment of psoriasis vulgaris was
developed following the EuroGuiDerm Guideline and Consensus Statement Development …

Multiple sclerosis treatment faces tremendous changes as a result of the approval of new
medications. The new medications have differing safety considerations and risks after long …

This evidence‐and consensus‐based guideline on the treatment of psoriasis vulgaris was
developed following the EuroGuiDerm Guideline and Consensus Statement Development …

Progressive multifocal leukoencephalopathy (PML) is a rare and potentially fatal condition
caused by a brain infection with JC polyomavirus (JCV). PML develops almost exclusively in …

Fingolimod (FTY720), an immunotherapeutic drug targeting the sphingosine-1-phosphate
receptor, is a widely used medication for relapsing-remitting multiple sclerosis (MS). Apart …

The implementation of a variety of immunosuppressive therapies has made drug-associated
progressive multifocal leukoencephalopathy (PML) an increasingly prevalent clinical entity …

Background: Injury to cells adjacent to an intracerebral hemorrhage (ICH) is likely mediated
at least in part by toxins released from the hematoma that initiate complex and interacting …

Multiple sclerosis treatment faces tremendous changes owing to the approval of new
medications, some of which are available as oral formulations. Until now, the four orally …

Progressive multifocal leukoencephalopathy (PML) has recently been described in psoriasis
or multiple sclerosis patients treated with fumaric acid esters (fumarates), who had …